# A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07266428/  
OnCo record `nct07266428` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of OTP-01 in advanced solid tumours, run by Ottimo Pharma Limited, now recruiting.

## Summary

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07266428 by Ottimo Pharma Limited, with 170 participants planned, started 2025-12-17 and due to reach its primary completion in 2028-12. Interventions recorded: OTP-01.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07266428
- Phase: 1/2
- Setting: Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
- Sponsor: Ottimo Pharma Limited
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT07266428: https://clinicaltrials.gov/study/NCT07266428

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07266428.json